Cardiff Oncology Shares Gain Favor as Analysts Revise Forecasts

Market experts are growing more optimistic about Cardiff Oncology’s financial trajectory. Following the biotechnology firm’s stronger-than-anticipated performance in February, analysts have now moved to upgrade their earnings projections for the start of fiscal year 2026.

Financial Estimates Revised Upward

In a recent research note dated March 26, the team at Noble Financial updated their model for Cardiff Oncology’s first quarter. The firm now anticipates a per-share loss of $0.14, a notable improvement from its previous forecast of a $0.19 loss. This adjustment comes directly on the heels of the company’s February quarterly report, which delivered a positive surprise by exceeding consensus estimates for both revenue and earnings.

Noble Financial has maintained its “Outperform” rating on the equity. While the analysts project a full-year 2026 net loss of $0.64 per share, they see significant upside potential, assigning a price target of $12.00. This target implies substantial growth from the current trading level of approximately $1.55 per share.

Should investors sell immediately? Or is it worth buying Cardiff Oncology?

Market Context and Performance

Currently valued with a market capitalization of around $106 million, Cardiff Oncology’s stock has experienced considerable volatility. Over the preceding 52-week period, its shares have traded within a wide band, reaching a low of $1.48 and a high of $4.56.

The foundation for the renewed analyst confidence was laid by recent revenue figures. The company reported sales of $0.24 million, nearly double the $0.13 million that market watchers had expected. The stark gap between the present share price and the elevated targets set by research firms underscores the market’s focus on upcoming clinical trial data expected later this year.

The broader analyst consensus currently categorizes the stock as a “Moderate Buy,” with the average price objective standing at $10.10.